Biowaiver

Biowaivers for Fixed-Dose Combination (FDC) Drug Products

Biowaivers for Fixed-Dose Combination (FDC) Drug Products

ByPharma Lesson Reading Time: 2 minutes

Fixed-dose combination (FDC) drug products present unique challenges in biowaiver assessments, as they involve multiple active pharmaceutical ingredients (APIs) with different physicochemical properties and release characteristics. Regulatory guidelines (USFDA, EMA, WHO) provide biowaiver provisions, but their applicability depends on several factors, such as API solubility, permeability, formulation type, and release mechanisms. Key Considerations for Biowaivers…

SUPAC Guidance on Qualitative Changes in Excipients

SUPAC Guidance on Qualitative Changes in Excipients

ByPharma Lesson Reading Time: 2 minutes

SUPAC Guidance on Qualitative Changes The USFDA SUPAC (Scale-Up and Post-Approval Changes) guidance categorizes formulation changes based on their impact on product performance. A qualitative change refers to the replacement or removal of an excipient, classified as a Level 3 change, which is considered major and requires regulatory approval. Key Regulatory Requirements for Level 3…

Biowaiver for Topical Dosage Forms

Biowaiver for Topical Dosage Forms

ByPharma Lesson Reading Time: 2 minutes

A Biowaiver for a topical dosage form refers to regulatory approval for marketing a generic topical product without conducting in vivo bioequivalence (BE) studies. Instead, equivalence is demonstrated using in vitro methods and other scientific justifications. Key Considerations for Biowaiver of Topical Dosage Forms Regulatory agencies such as USFDA, EMA, and WHO provide guidelines for…

Biowaiver Criteria for Multiple Strengths Across Regulatory Bodies

Biowaiver Criteria for Multiple Strengths Across Regulatory Bodies

ByPharma Lesson Reading Time: 2 minutes

When BE is demonstrated for one strength of a drug product, regulatory agencies allow a biowaiver for additional strengths under certain conditions. The key criteria vary across USFDA, EMA, WHO, MHRA, TGA, and CDSCO but are largely aligned on fundamental principles. USFDA Biowaiver Criteria Biowaiver is allowed for additional strengths if: EMA Biowaiver Criteria Follows…

End of content

End of content